Celcuity Inc.
CELC
Updated: 24/09/2026, 15:01:00
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
No summaries found.
- Share price
- $79.99
- Market cap
- $3.90B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Brian F. Sullivan
- Employees
- 155
- IPO date
- 19/09/2017
- Beta
- 0.164
- Last dividend
- $0.00
- Day range
- $79.40 – $85.05
- 52-week range
- $44.42 – $151.02
- 1-day performance
- -4.89%
- 1-year performance
- 80.08%
- Current drawdown (1Y)
- -47.03%
- CIK
- 0001603454
- CUSIP
- 15102K100
- ISIN
- US15102K1007
- Created
- 07/12/2025, 03:15:06
- Last update
- 24/09/2026, 15:01:00
Track Celcuity Inc. with an AI analyst
See which prediction-market events move CELC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 10/06/2026, 17:32:13
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
GlobeNewsWire • STOCK • 04/06/2026, 00:13:00
Celcuity (NASDAQ:CELC) Faces Volatility After Mixed Clinical Trial Data
Market Data • Market Data • 03/06/2026, 16:20:19
Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
Seeking Alpha • STOCK • 03/06/2026, 11:33:26
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
GlobeNewsWire • STOCK • 03/06/2026, 09:19:00
Celcuity plunges after experimental breast cancer treatment data disappoints
Reuters • STOCK • 02/06/2026, 15:20:26
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
GlobeNewsWire • STOCK • 01/06/2026, 10:30:00
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 14/05/2026, 22:20:42
Celcuity Q1 Earnings Call Highlights
MarketBeat • STOCK • 14/05/2026, 21:11:03
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewsWire • STOCK • 14/05/2026, 18:01:00
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
GlobeNewsWire • STOCK • 01/05/2026, 19:03:00
Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers
Seeking Alpha • STOCK • 29/04/2026, 12:21:12